After 72 weeks of treatment, people taking Zepbound lost about 50 pounds, compared with 33 pounds for those taking Wegovy. The weight loss drug Zepbound (tirzepatide) led to 50 percent more weight ...

Cigna's Evernorth business caps GLP-1 drug copays at $200 or less, aiming to boost affordability for patients and cut costs ...

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

For a limited time, Wegovy will be available to new patients at $199 for the first month, Novo Nordisk said Thursday.

Cigna has announced a deal to cap client copays on popular GLP-1 weight loss drugs by Eli Lilly and Novo Nordisk at $200 per ...

Hims & Hers stock took a nosedive after Cigna’s Evernorth division announced a $200 monthly cap on popular weight-loss drugs ...

The agreements cap patients’ monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs ...

Evernorth has capped antiobesity drug monthly co-pays at $200 in a move to improve access and affordability amid new drug ...

Shares of telehealth provider Hims & Hers Health Inc. (HIMS) dropped over 3% on Thursday after Cigna Group’s (CI) Evernorth ...

Health plan sponsors are also expected to see a reduction in the net cost per prescription of GLP-1 medications to treat obesity.

Only half of health insurer Cigna’s (NYSE:CI) clients currently cover the popular GLP-1 weight loss drugs Wegovy and Zepbound because of their high costs. But the company’s pharmacy benefits unit ...

An investigation by The Guardian finds the insurance giant UnitedHealth Group quietly paid thousands in bonuses to nursing home facilities that helped it gain Medicare enrollees and reduce ...